Viatris Inc. · NASDAQ:VTRS
Viatris — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
10 slides from Viatris's conference presentation, Jan 13, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
44 Annual J.P. Morgan th Healthcare Conference This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties January 13, 2026 is strictly prohibited. © 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures Forward Looking Statements This presentation contains “forward-looking statements”. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may i
Slide 3: Viatris at a Glance
Viatris at a Glance Financial Results over 12 Months Ended September 30, 2025 (1) $14.1B Total Revenues $4.1B Adjusted EBITDA $2.32 Adjusted EPS $2.2B Free Cash Flow Ex Transaction-related Costs (2) Well-Diversified Geographically Global Iconic Brands 16% •Net Sales by Segment 25% • North America 9%
Slide 4: Delivered on Our 2025 Strategic Priorities
Delivered on Our 2025 Strategic Priorities Drove strong commercial execution across our global portfolio Advanced our pipeline, including five positive Phase 3 readouts Prioritized capital return with >$1B returned to shareholders (1) Targeted accretive regional business development, including our a
Slide 5: Strategic Setup for 2026
Strategic Setup for 2026 Anticipated Enterprise-wide Significant Cash Meaningful Launches Strategic Review Flow Generation Pipeline Milestones collectively serve to expected to deliver for accretive for selatogrel and strengthen our outlook meaningful net business development cenerimod potentially f
Slide 6: Key Recent and Upcoming Catalysts
Key Recent and Upcoming Catalysts Anticipated Regulatory Decisions and Launches Anticipated Milestones Asset Region Timing Asset Milestone Spydia® Launched Cenerimod Full Enrollment Japan H1 2026 Status Epilepticus Systemic Lupus Erythematosus Sotagliflozin Ex-U.S., Selatogrel Full Enrollment H1 202
Slide 7: GAAP / Non-GAAP Reconciliations
GAAP / Non-GAAP Reconciliations This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Via
Slide 8: U.S. GAAP Net Loss to EBITDA and Adjusted EBITDA
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) U.S. GAAP Net Loss to EBITDA and Adjusted EBITDA Three Months Ended Twelve Months Ended December 31, 2024 March 31, 2025 June 30, 2025 September 30, 2025 September 30, 2025 U.S. GAAP net loss......
Slide 9: U.S. GAAP Net Loss to Adjusted Net Earnings and Adjusted EPS
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) U.S. GAAP Net Loss Earnings to Adjusted Net Earnings and U.S. GAAP Diluted Loss Per Share to Adjusted EPS Three Months Ended Twelve Months Ended December 31, 2024 March 31, 2025 June 30, 2025 Septe
Slide 10: Free Cash Flow and Free Cash Flow Excluding Transaction-related Costs
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Free Cash Flow and Free Cash Flow Excluding Transaction-related Costs Three Months Ended Twelve Months Ended December 31, 2024 March 31, 2025 June 30, 2025 September 30, 2025 September 30, 2025 U.S
Viatris — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix